AzTrials
AzTrials

Lung CancerNCT02597738

A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine

A study testing Fresh tissue biopsy and Blood/Urine Sample Collection in people with Lung Cancer and Head and Neck Cancer, run by University of Arkansas at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). Read more about this study

Who is it for?
Ages 18 to 99 yearsHealthy volunteers can take part
Conditions the study is for
Lung Cancer, Head and Neck Cancer
What is being tested?
Fresh tissue biopsy and Blood/Urine Sample Collection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
330 participants
Where
1 siteUnited States
Study dates
Jan 2016to Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Cohort A (Lung/Head and Neck Cancer Group) Inclusion criteria:

  1. Unresectable metastatic lung cancer or head and neck cancer or other solid tumor malignancy
  2. Current or Former Smokers with greater than or equal to 10 pack year smoking history
  3. Candidates for standard or experimental treatment as determined by their treating physician
  4. Age 18 years and older
  5. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)

Cohort A (Lung/Head and Neck Cancer Group) Exclusion criteria:

  1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen
  2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.
  3. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol
  4. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol
  5. Other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen

Cohort B (Chronic Inflammatory disease) Inclusion criteria:

  1. Chronic inflammatory disease including but not limited to:
  • Systematic Lupus Erythematosus
  • Rheumatoid arthritis
  • Hepatitis C
  • Ankylosing Sponsylitis
  • Scleroderma
  1. No history of smoking or quit smoking within the last six months
  2. Age 18 years and older
  3. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)

Cohort B (Chronic inflammatory disease) Exclusion criteria:

  1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen. 2. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol.
  2. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol.
  3. Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration.
  4. No current steroid treatment or treatment within the last 3 months.

Cohort C (At risk for lung cancer) Inclusion criteria:

  1. Age 45-74 years
  2. Former or current smokers with a 30 or more pack-years of cigarette smoking history
  3. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)

Cohort C (At risk for lung cancer) Exclusion criteria:

  1. Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration.
  2. History of lung cancer
  3. History of removal of any portion of the lung, excluding needle biopsy
  4. Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment
  5. Recent hemoptysis
  6. Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment.
  7. History of abnormal chest CT examination suspicious for cancer in the 18 months prior to eligibility assessment.
  8. Chronic inflammatory disease including but not limited to:
  • Systematic Lupus Erythematosus
  • Rheumatoid arthritis
  • Hepatitis C
  • Ankylosing Sponsylitis
  • Scleroderma

Cohort D (healthy people who exercise) Inclusion criteria:

  1. Age 18 years and older
  2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
  3. Must complete and self-report vigorous exercise for 30 minutes

Cohort D (healthy people who exercise) Exclusion criteria:

  1. People will be excluded if they have self reported any of the following conditions: diabetes, heart disease, autoimmune disorders or hepatitis.

Cohort E (lung cancer with planned resection) Inclusion criteria:

  1. Age 18 years and older
  2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
  3. Lung cancer with planned resection.

Cohort E (lung cancer with planned resection) Exclusion criteria:

  1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol
  2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.

Cohort F (Any solid tumor cancer with radiation therapy) Inclusion criteria:

  1. Age 18 years and older
  2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB)
  3. Any solid tumor cancer and will receive radiation therapy.

Cohort F (Any solid tumor cancer with radiation therapy) Exclusion criteria:

  1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol 3. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

Other trials in United States

About this study

Official title: Scientific and Methodological Advancements in Human Specimens to Further the Development of Lung Cancer-based Precision Medicine - A Feasibility Study

The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer screening (synergy with imaging). A co-clinical trial approach, with integrative analyses leveraging data from the treatment of genetic mouse models of lung cancer along with clinical samples and data from lung cancer patients, will be used to elucidate genomic background metrics, identify cell free DNA mutations, and further refine the liquid biopsy approach. Blood and urine samples will be analyzed for different genetic components. The tissue biopsy will be implanted into a mouse and after the cancer grows in the mouse the cancer DNA from the mouse will be compared with the human blood.

Read the detailed description

This is a feasibility study to collect tumor and peripheral blood and urine of patients with lung cancer, or head and neck cancer, or other solid tumor who receive treatment. Blood and urine will also be collected from subjects without cancer to assess non cancer profiles. To conduct this study, a total of 30 study-eligible subjects of all races and ethnicities, aged 18 years or older with a diagnosis of cancer of the lung or head and neck cancer or other solid tumor malignancy (Cohort A), will be enrolled and have their tumor collected once for molecular profiling and xenograft development and blood collected at prespecified time intervals until completion of treatment for liquid biopsy analysis (targeted sequencing, whole exome sequencing, whole genome sequencing). A total of 140 study-eligible subjects of all races and ethnicities ages 18 years or older will be enrolled in the non-lung cancer control subgroups for chronic inflammatory disorder (Cohort B), people at risk to develop lung cancer (Cohort C) and healthy people who complete vigorous exercise (Cohort D). A total of 180 subjects will be enrolled into the resection and radiation therapy cancer cohorts (Cohorts E and F).

Being tested
Fresh tissue biopsy, Blood/Urine Sample Collection
Medical subject headings
Lung Neoplasms, Head and Neck Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fresh tissue biopsyOther

    Fresh tissue biopsy will be collected.

  • Blood/Urine Sample CollectionOther

    A one time blood sample will be collected.

Study groups in NCT02597738
Study groupRoleWhat they receive
Lung/ Head and Neck Cancer GroupExperimentalBlood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five.
Receives: Other: Fresh tissue biopsy; Other: Blood/Urine Sample Collection
Chronic inflammatory diseaseExperimentalBlood/Urine Sample Collection A one time blood and urine sample collection will be completed.
Receives: Other: Blood/Urine Sample Collection
At risk for lung cancerExperimentalBlood/Urine Sample Collection A one time blood and urine sample collection will be completed.
Receives: Other: Blood/Urine Sample Collection
Healthy people who exerciseExperimentalBlood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise.
Receives: Other: Blood/Urine Sample Collection
Lung cancer with planned resectionExperimentalBlood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits. Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded.
Receives: Other: Fresh tissue biopsy; Other: Blood/Urine Sample Collection
Solid tumor cancer w/ radiation therapyExperimentalBlood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years.
Receives: Other: Blood/Urine Sample Collection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measurement of genomic profile

    Genomic changes causing lung cancer evolve over the course of illness. The genetic changes may serve as a biomarker for diagnosis and response to treatment. These changes will be measured in human specimens and co-cultured in mice.

    Measured: 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2015 (estimated)
  2. Study startJan 2016
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
330 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02597738
Sponsor's protocol ID
204803
Status last verified
May 2026
First submitted
28 Oct 2015
Last updated
29 May 2026
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Fresh tissue biopsy and Blood/Urine Sample Collection in people with Lung Cancer and Head and Neck Cancer, run by University of Arkansas at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measurement of genomic profile (time frame: 15 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in